Rebecca Byam is Chief Financial Officer of HCW Biologics Inc.. Currently has a direct ownership of 1.38 Million shares of HCWB, which is worth approximately $594,220. The most recent transaction as insider was on Feb 20, 2024, when has been sold 760,714 shares (Common Stock) at a price of $1.4 per share, resulting in proceeds of $1,064,999. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 1.38M
0% 3M change
122.46% 12M change
Total Value Held $594,220

Rebecca Byam Transaction History

Date Transaction Value Shares Traded Shares Held Form
Feb 20 2024
BUY
Grant, award, or other acquisition
$1,064,999 $1.4 p/Share
760,714 Added 35.5%
1,381,909 Common Stock
Oct 19 2023
BUY
Exercise of conversion of derivative security
$6,614 $0.14 p/Share
47,249 Added 7.07%
621,195 Common Stock
Sep 13 2023
BUY
Open market or private purchase
$10,500 $2.1 p/Share
5,000 Added 0.86%
573,946 Common Stock
Sep 12 2023
BUY
Open market or private purchase
$10,450 $2.09 p/Share
5,000 Added 0.87%
568,946 Common Stock
Sep 11 2023
BUY
Open market or private purchase
$10,250 $2.05 p/Share
5,000 Added 0.88%
563,946 Common Stock
Sep 08 2023
BUY
Open market or private purchase
$10,100 $2.02 p/Share
5,000 Added 0.89%
558,946 Common Stock
Sep 07 2023
BUY
Open market or private purchase
$9,750 $1.95 p/Share
5,000 Added 0.89%
553,946 Common Stock
Sep 06 2023
BUY
Open market or private purchase
$9,750 $1.95 p/Share
5,000 Added 0.9%
548,946 Common Stock
Jun 09 2023
BUY
Open market or private purchase
$41,200 $2.06 p/Share
20,000 Added 3.55%
543,946 Common Stock
Jun 08 2023
BUY
Open market or private purchase
$10,378 $2.21 p/Share
4,696 Added 0.89%
523,946 Common Stock
Jun 07 2023
BUY
Open market or private purchase
$40,599 $2.03 p/Share
20,000 Added 3.71%
519,250 Common Stock
Jun 06 2023
BUY
Open market or private purchase
$34,692 $1.82 p/Share
19,062 Added 3.68%
499,250 Common Stock
Jun 05 2023
BUY
Open market or private purchase
$33,400 $1.67 p/Share
20,000 Added 4.0%
480,188 Common Stock
May 26 2023
BUY
Open market or private purchase
$33,200 $1.66 p/Share
20,000 Added 4.17%
460,188 Common Stock
May 25 2023
BUY
Open market or private purchase
$32,400 $1.62 p/Share
20,000 Added 4.35%
440,188 Common Stock
May 24 2023
BUY
Open market or private purchase
$32,200 $1.61 p/Share
20,000 Added 4.54%
420,188 Common Stock
May 23 2023
BUY
Open market or private purchase
$7,906 $1.57 p/Share
5,036 Added 1.24%
400,188 Common Stock
May 22 2023
BUY
Open market or private purchase
$51,178 $1.53 p/Share
33,450 Added 7.8%
395,152 Common Stock
Nov 02 2022
BUY
Exercise of conversion of derivative security
$4,725 $0.14 p/Share
33,750 Added 8.53%
361,702 Common Stock
Sep 14 2022
BUY
Open market or private purchase
$38,700 $2.58 p/Share
15,000 Added 4.37%
327,952 Common Stock
Sep 13 2022
BUY
Open market or private purchase
$38,700 $2.58 p/Share
15,000 Added 4.57%
312,952 Common Stock
Sep 12 2022
BUY
Open market or private purchase
$39,750 $2.65 p/Share
15,000 Added 4.79%
297,952 Common Stock
Aug 31 2022
BUY
Open market or private purchase
$25,600 $2.56 p/Share
10,000 Added 3.41%
282,952 Common Stock
Aug 30 2022
BUY
Open market or private purchase
$18,360 $2.55 p/Share
7,200 Added 2.57%
272,952 Common Stock
Aug 29 2022
BUY
Open market or private purchase
$25,700 $2.57 p/Share
10,000 Added 3.63%
265,752 Common Stock
RB

Rebecca Byam

Chief Financial Officer
Miramar, FL

Track Institutional and Insider Activities on HCWB

Follow HCW Biologics Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells HCWB shares.

Notify only if

Insider Trading

Get notified when an Hcw Biologics Inc. insider buys or sells HCWB shares.

Notify only if

News

Receive news related to HCW Biologics Inc.

Track Activities on HCWB